HOVON 146
A phase II trial where blinatumomab is added to prophase and consolidation therapy in precursor B-acute lymphoblastic leukemia in adults.
Study Treatments
Blinatumomab IV added to prophase and consolidation therapy.
Inclusion criteria:
- Primary CD19 positive precursor B-ALL (excluding mature B-cell ALL and B-lymphoblastic lymphoma, but including Philadelphia positive/BCR-ABL positive ALL) and CD19 positive mixed phenotype acute lymphoblastic leukemia (MPAL)
- Patients aged 18 to 70 years inclusive
Exclusion criteria
- Mature B-cell leukemia/lymphoma, B-lymphoblastic lymphoma, isolated extramedullary disease
- Acute undifferentiated leukemia
- Severe pulmonary dysfunction
- Severe cardiovascular disease
Participating sites
- AZ St. Jan
- ZNA Antwerpen
- UZA